


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Progesterone (8CI)

OTHER NAMES:

CN .DELTA.4-Pregnene-3,20-dione

CN Agolutin

CN Bio-luton

CN Corlutin

CN Corlutina

CN Corluvite

CN Corporin

CN Corpus luteum hormone

CN Crinone

CN Cyclogest

CN Flavolutan

CN Fologenon

CN Gesterol

CN Gestiron

CN Gestone

CN Gestormone

CN Gestron

CN Glanducorpin

CN Gynlutin

CN Gynolutone

CN Hormoflaveine

CN Hormoluton

CN Lipo-Lutin

CN Lucorteum Sol

CN Lugesteron

CN Luteal Hormone

CN Luteinique

CN Luteocrin normale

CN Luteodyn

CN Luteogan

CN Luteohormone

CN Luteol

CN Luteopur

CN Luteosan

CN Luteostab

CN Luteovis

CN Luteum

CN Lutex

CN Lutidon

CN Lutin

CN Lutociclina

22


CN Lutocuclin M  
CN Lutocyclin  
CN Lutocyclin M  
CN Lutocyclin  
CN Lutoform  
CN Lutogyl  
CN Lutren  
CN Lutromone  
CN Nalutron

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

=> d rn str cn

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 1961-77-9 REGISTRY

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CN Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy- (6CI, 7CI, 8CI, 9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN 6-Chloro-6-dehydro-17-hydroxyprogesterone  
CN 6-Chloro-6-dehydro-17.alpha.-hydroxyprogesterone  
CN Chlormadinon  
CN **Chlormadinone**

=> s 11 and progesterone

L2 6 L1 AND PROGESTERONE

=> d 1-6

L2 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2004 Univentio on STN  
AN 2001022959 PCTFULL ED 20020820  
TIEN METHOD OF TREATING INFLAMMATORY CONDITIONS WITH PROGESTERONE  
OR PROGESTERONE ANALOGS  
TIFR METHODE DE TRAITEMENT DE CONDITIONS INFLAMMATOIRES AU MOYEN DE LA  
PROGESTERONE OU D'ANALOGUES DE LA PROGESTERONE  
IN SCHREIBER, Alan, D.  
PA UNIVERSITY OF PENNSYLVANIA;  
SCHREIBER, Alan, D.  
DT Patent  
PI WO 2001022959 A2 20010405  
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ  
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP  
KE KG KP KR KZ LC LK LS LT LU LV MA MD MG MK MN MW MX  
MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA  
UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB  
GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR  
NE SN TD TG  
AI WO 2000-US26501 A 20000927  
PRAI US 1999-60/156,434 19990928  
US 2000-09/658,867 20000908  
ICM A61K031-00

L2 ANSWER 2 OF 6 USPATFULL on STN

AN 2004:51523 USPATFULL

TI Method of treating inflammatory conditions with progesterone  
or progesterone analogs

IN Schreiber, Alan D., Philadelphia, PA, UNITED STATES  
PA UNIVERSITY OF PENNSYLVANIA (U.S. corporation)

PI US 2004038954 A1 20040226

AI US 2003-601756 A1 20030624 (10)

RLI Continuation of Ser. No. US 2000-658867, filed on 8 Sep 2000, GRANTED,  
Pat. No. US 6610674

PRAI US 1999-156434P 19990928 (60)

DT Utility

FS APPLICATION

LN.CNT 775

INCL INCLM: 514/177.000

NCL NCLM: 514/177.000

IC [7]

ICM: A61K031-57

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 6 USPATFULL on STN

AN 2003:228323 USPATFULL

TI Method of treating inflammatory conditions with progesterone  
analogs

IN Schreiber, Alan D., Philadelphia, PA, United States

PA University of Pennsylvania, Philadelphia, PA, United States (U.S.  
corporation)

PI US 6610674 B1 20030826

AI US 2000-658867 20000908 (9)

PRAI US 1999-156434P 19990928 (60)

DT Utility

FS GRANTED

LN.CNT 936

INCL INCLM: 514/177.000  
INCL INCLS: 514/178.000; 514/181.000  
NCL NCLM: 514/177.000  
NCL NCLS: 514/178.000; 514/181.000  
IC [7]  
ICM: A61K031-56  
EXF 514/177; 514/178; 514/181  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 6 USPATFULL on STN  
AN 91:104199 USPATFULL  
TI Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes  
IN Schreiber, Alan D., Philadelphia, PA, United States  
PA University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 5075321 19911224  
AI US 1988-159714 19880224 (7)  
RLI Continuation-in-part of Ser. No. US 1987-30028, filed on 24 Mar 1987, now abandoned And a continuation-in-part of Ser. No. US 1987-89790, filed on 27 Aug 1987, now patented, Pat. No. US 4902681  
DT Utility  
FS Granted  
LN.CNT 641  
INCL INCLM: 514/317.000  
INCL INCLS: 514/319.000; 514/324.000  
NCL NCLM: 514/317.000  
NCL NCLS: 514/319.000; 514/324.000  
IC [5]  
ICM: A16K031-56  
EXF 514/317; 514/319; 514/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 6 USPATFULL on STN  
AN 90:19561 USPATFULL  
TI Inhibition of immune clearance using progesterone analogues  
IN Schreiber, Alan D., Philadelphia, PA, United States  
PA Trustees of The University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 4908358 19900313  
AI US 1988-159706 19880224 (7)  
RLI Continuation-in-part of Ser. No. US 1987-89790, filed on 27 Aug 1987  
DT Utility  
FS Granted  
LN.CNT 461  
INCL INCLM: 514/177.000  
INCL INCLS: 514/178.000; 514/885.000  
NCL NCLM: 514/177.000  
NCL NCLS: 514/178.000; 514/858.000  
IC [4]  
ICM: A61K031-56  
EXF 514/177; 514/178; 514/181; 435/13; 260/397.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 6 USPATFULL on STN  
AN 90:13416 USPATFULL  
TI Inhibition of immune clearance using progesterone analogues  
IN Schreiber, Alan D., Philadelphia, PA, United States  
PA University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
PI US 4902681 19900220

=> d his

(FILE 'HOME' ENTERED AT 12:22:12 ON 01 SEP 2004)

FILE 'STNGUIDE' ENTERED AT 12:22:16 ON 01 SEP 2004

FILE 'HOME' ENTERED AT 12:22:21 ON 01 SEP 2004

FILE 'EUROPATFULL, FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL,  
USPAT2' ENTERED AT 12:22:31 ON 01 SEP 2004

E SCHREIBER ALAN/IN

L1 25 S E4

L2 6 S L1 AND PROGESTERONE

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 12:31:36 ON 01 SEP 2004

E SCHREIBER ALAN/AU

L3 221 S E3-E4

L4 4 S L3 AND PROGESTERONE

L5 27 S L3 AND (PROGESTERONE OR INFLAMMAT? OR ALLERG?)

FILE 'REGISTRY' ENTERED AT 12:42:44 ON 01 SEP 2004

E DIHYDROPROGESTERONE/CN

E 16 17 DIHYDROPROGESTERONE/CN

E DIHYDROXYPROGESTERONE/CN

L6 1 S E3

E PROGESTERONE/CN

L7 1 S E3

E ALLYESTRENOL/CN

FILE 'CAPLUS' ENTERED AT 12:48:47 ON 01 SEP 2004

L8 2 S ALLYESTRENOL

L9 11107 S DIHYDROXYPROGESTERONE OR ALLYESTRENOL OR CHLORMADINONE OR EST

L10 980 S NORETHANDROLONE OR ?ESTRENOL

L11 11774 S L9 OR L10

L12 232540 S INFLAMMAT? OR COLITIS OR CROHN? OR PROCTITIS OR ALLERG? OR GE

L13 66 S L11(L)L12

L14 48 S L13 NOT PY>=1999

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:19:06 ON 01 SEP 2004

L15 502252 S INFLAMMAT? (5A)BOWEL OR COLITIS OR CROHN? OR PROCTITIS OR ALL

L16 16 S L15(L)L11

L17 15 DUP REM L16 (1 DUPLICATE REMOVED)

FILE 'ADISCTI, IMSPRODUCT, DRUGU, IMSRESEARCH' ENTERED AT 13:31:49 ON 01  
SEP 2004

L18 0 S L17

L19 40 S L16

L20 30 S L19 NOT PY>=1999

=>

AI US 1987-89790 19870827 (7)  
DT Utility  
FS Granted  
LN.CNT 304  
INCL INCLM: 514/177.000  
INCLS: 514/178.000; 514/885.000  
NCL NCLM: 514/177.000  
NCLS: 514/178.000; 514/885.000  
IC [4]  
ICM: A61K031-56  
EXF 514/177; 514/178; 514/181; 435/13; 260/397.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ti 1-30

L20 ANSWER 1 OF 30 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
TI Exacerbation of premenstrual asthma caused by an oral contraceptive.

L20 ANSWER 2 OF 30 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
TI Development of erythema nodosum in the course of oestrogen replacement therapy.  
ADIS TITLE: Conjugated estrogens, dydrogesterone, medroxyprogesterone: adverse reactions.  
Erythema nodosum  
Three case reports.

L20 ANSWER 3 OF 30 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN  
TI Impact of side-effects associated with endocrine treatments for advanced breast cancer: clinicians' and patients' perceptions.

L20 ANSWER 4 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Inhibition of skin 11-beta- hydroxysteroid dehydrogenase activity in vivo potentiates the anti-inflammatory actions of glucocorticoids.

L20 ANSWER 5 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Dermatology therapy update.

L20 ANSWER 6 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Cushing's syndrome induced by megestrol acetate in a patient with AIDS.

L20 ANSWER 7 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Intractable hiccups induced by the use of megestrol acetate.

L20 ANSWER 8 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Repeated treatment with horse antilymphocyte globulin for severe aplastic anemia.

L20 ANSWER 9 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI New hormones and antineoplastic agents in tumor therapy.

L20 ANSWER 10 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Progestin-only oral contraception: a comprehensive review.

L20 ANSWER 11 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma.

L20 ANSWER 12 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Hypersensitivity to Topical Corticosteroids.

L20 ANSWER 13 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Combined Oral Contraceptives: Acceptability and Effective Use.

L20 ANSWER 14 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Combined Oral Contraceptives: Risks and Benefits.

L20 ANSWER 15 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Localized Cutaneous Reaction to Intravenous Pentamidine.

L20 ANSWER 16 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Management of Relapsing Disease in Prostate Cancer.

---

L20 ANSWER 17 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Chronic Urticaria Angioedema and Anaphylaxis Caused by Birth Control Pills.

L20 ANSWER 18 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Gastrointestinal Disease and Oral Contraception.

L20 ANSWER 19 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI The Barrier Function of the Skin in Relation to Percutaneous Absorption

of Drugs.

L20 ANSWER 20 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Influence of Medication on Male Fertility.

L20 ANSWER 21 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Treatment of Prostate Cancer.

L20 ANSWER 22 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Hormone and Chemotherapy of Mamma Carcinoma.

L20 ANSWER 23 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI What is Certain in the Treatment of Acne. (Question).

L20 ANSWER 24 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI The Reversibility of Female Infertility Caused by Salazosulfapyridine.

L20 ANSWER 25 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Various Doses of Megestrol Acetate in the Treatment of Metastatic Breast  
Cancer-Clinical and Endocrinological Investigations.

L20 ANSWER 26 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Phase II Study of Thymosin Fraction 5 in the Treatment of Metastatic  
Renal Cell Carcinoma.

L20 ANSWER 27 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Premenstrual Syndrome - Every Month. (Question).

L20 ANSWER 28 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Primary Dysmenorrhea: Current Views on Etiology and Treatment.

L20 ANSWER 29 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Prostaglandins and Nonsteroidal Antiinflammatory Drugs in Dysmenorrhea.

L20 ANSWER 30 OF 30 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN  
TI Immediate Results of Sarcolysin Treatment of Patients With Malignant  
Tumors of Ovaries.

ACCESSION NUMBER: 1991-10061 DRUGU P E S

TITLE: Gastrointestinal Disease and Oral Contraception.

AUTHOR: Hanker J P

LOCATION: Munster, Germany, West

SOURCE: Am.J.Obstet.Gynecol. (163, No. 6, Pt. 2, 2204-07, 1990) 57

Ref.

CODEN: AJOGAH ISSN: 0002-9378

AVAIL. OF DOC.: Zentrum fuer Fraeuenheilkunde, Albert-Schweitzer-Strasse 33,  
D-4400 Muenster, Germany.

LANGUAGE: English -

DOCUMENT TYPE: Journal

FIELD AVAIL.: AB; LA; CT

FILE SEGMENT: Literature

AN 1991-10061 DRUGU P E S

AB The effects of GI disease on oral contraceptive (OC) efficacy are discussed. The enterohepatic circulation of OC including ethynodiol (EE), mestranol, norethisterone, levonorgestrel, desogestrel, cyproterone acetate (CPA), **chlormadinone acetate**, noretdinodrel, etynodiol, lynestrenol and norethisterone acetate, and its modification by other drugs including ampicillin and antacids is discussed. The effects of chronic **inflammatory bowel** disease of OC absorption and efficacy are considered. OC may gave an etiological role in the development on Crohn's disease.  
(congress).

ABEX The low doses of estrogens and progestogens used in OC mean than any dietary factors affecting bioavailability are relevant to contraceptive efficacy. EE metabolism is described. If EE undergoes enterohepatic circulation, any disruption would increase the risk of contraceptive failure. There is no convincing evidence that ampicillin, erythromycin or trimethoprim effects EE metabolism. In 12 women given an antacid (magnesium trisilicate and aluminum hydroxide) there was no change in the bioavailability of EE, norethisterone acetate or levonorgestrel. Mestranol is rapidly converted to EE and undergoes enterohepatic circulation. Progestogens (norethisterone, levonorgestrel, desogestrel, CPA and **chlormadinone acetate**) do not undergo enterohepatic circulation. Noretdinodrel, etynodiol, lynestrenol and norethisterone acetate are metabolized to norethisterone. Desogestrel is converted to 3-ketodesogestrel and norgestimate to norgestrel-17-beta-acetate and levonorgestrel. OC use is associated with an increased risk of Crohn's disease. Ulcerative **colitis** or ileostomy may result in reduced OC absorption, as may small bowel but not colonic diarrhea, leading to reduced efficacy. (E33/JB)

L17 ANSWER 2 OF 15 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on  
STN

ACCESSION NUMBER: 1996:341351 BIOSIS  
DOCUMENT NUMBER: PREV199699063707  
TITLE: High gastrointestinal tract inflammatory disease probably  
due to progestogen use.  
AUTHOR(S): Daghfous, Riadh; Hedi Loueslati, Mohamed; El Aidli, Sihem;  
Srairi, Samia; Lakhal, Mohamed; Belkahia, Chalbi  
CORPORATE SOURCE: Cent. Natl. Pharmacovigilance, Hopital Charles-Nicolle,  
1006 Tunis, Tunisia  
SOURCE: Gastroenterologie Clinique et Biologique, (1995) Vol. 19,  
No. 10, pp. 853-854.  
CODEN: GCBIDC. ISSN: 0399-8320.  
DOCUMENT TYPE: Article  
LANGUAGE: French  
ENTRY DATE: Entered STN: 26 Jul 1996  
Last Updated on STN: 26 Jul 1996  
IT Miscellaneous Descriptors  
BIOPSY; **CHLORMADINONE**; DRUG SIDE EFFECTS; ENDOSCOPY;  
**ESOPHAGITIS**; ESTROGEL; GLOSSITIS; MENOPAUSE; MICROISCHEMIA;  
NONSPECIFIC INFLAMMATION; PATHOPHYSIOLOGY

ACCESSION NUMBER: 1971:74102 CAPLUS

DOCUMENT NUMBER: 74:74102

TITLE: Effect of adrenalectomy and endocrine substances on restraint-induced acute gastric ulceration

AUTHOR(S): Ozdemir, I. Ayhan; Zimmermann, Bernard

CORPORATE SOURCE: Sch. Med., West Virginia Univ., Morgantown, WV, USA

SOURCE: Surgical Forum (1970), 21, 304-5

CODEN: SUFOAX; ISSN: 0071-8041

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Rats were restrained for 20 hr, and ulcers that developed were counted.

Groups of restrained and control (fasted only) rats were treated with cortisone (75 mg/kg/day), 17-hydroxyprogesterone (125 mg/kg), vitamin A (50 I.U./g) and ACTH (50 I.U./kg). Adrenalectomized rats were highly sensitive to both fasting and restraint. Restraint-induced gastric ulcers differed sharply from cortisone ulcers being characterized by ischemic and coagulative necrosis without evidence of **inflammation** or epithelial mucin. These ulcers were not prevented by vitamin A.

Cortisone and 17-hydroxyprogesterone greatly reduced the incidence and severity. There was an unexplained ulcer-abetting effect of ACTH.